不同中药注射剂辅助治疗肝癌的有效性与经济学评价  

Different Chinese Patent Medicine Injections as Adjunctive Therapy for Liver Cancer: An Efficacy and Pharmacoeconomic Evaluation

作　　者：谭兵[1] 吴府容[1] 康强强[1] 王勇[1] 

机构地区：[1]重庆市肿瘤医院放疗科,重庆400030

出　　处：《中国医院用药评价与分析》2013年第6期494-496,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:比较不同中药注射剂辅助治疗肝癌的成本-效果。方法:将2011年1月—2012年3月我院150例晚期肝癌患者以随机抽样法分为5组,即艾迪注射液组、康莱特注射液组、榄香烯注射液组、消癌平注射液组与对照组,每组各30例。所有患者均给予丝裂霉素、吡柔比星、顺铂的介入治疗。除对照组外,其他4组患者分别辅以上述4种不同中药注射剂予以治疗,运用药物经济学方法评价5组的成本-效果。结果:艾迪注射液组、康莱特注射液组、榄香烯注射液组与消癌平注射液组成本-效果比分别为113.05、185.14、183.83、184.95,对照组为125.84,艾迪注射液组成本-效果比明显低于其他3组中药注射剂组,组间比较差异有统计学意义(P<0.05)。艾迪注射液组、康莱特注射液组、榄香烯注射液组与消癌平注射液组治疗3个月后疾病控制率分别为89.64%、84.62%、89.64%、80.77%,均高于对照组的57.68%,组间比较差异有统计学意义(P<0.05)。结论:4种中药注射剂辅助治疗肝癌均优于对照组,艾迪注射液组经济学成本优于其他3组中药注射剂组。晚期肝癌患者在介入治疗基础上辅以艾迪注射液是较为经济的治疗方案。OBJECTIVE ：To evaluate cost-effectiveness of different Chinese patent medicine injections as adjunctive therapy for liver cancer. METHODS ： 150 patients with advanced liver cancer treated in our hospital from January 2011 to March 2012 were randomly assigned to 5 groups of 30 cases each treated with Aidi Injection, Kanglaite Injection, Elemene Injection, Xiaoaiping Injection or placebo plus interventional therapy with mitomycin, pirarubicin and cisplatin. The cost-effectiveness of five groups was analyzed using the method in pharmacoeconomics. RESULTS： The cost- effectiveness ratios in Aidi Injection group, Kanglaite Injection group, Elemene Injection group and Xiaoaiping Injection group were 113.05, 185.14, 183.83 and 184.95, respectively, as compared with 125.84 in the control group, evidently, the cost-effectiveness ratio in Aidi Injection group was significantly lower than in the other three groups, showing significant differences among groups （P 〈 0. 05 ）. The rates of disease control in Aidi Injection group, Kanglaite Injection group, Elemene Injection group and Xiaoaiping Injection group at 3 month were 89. 64%, 84. 62%, 89. 64% and 80. 77%, respectively, all were higher than in the control group （57.68%）, and the differences among groups were significant （P 〈0. 05 ）. CONCLUSION： All of the 4 Chinese patent medicine injections were superior to the placebo （control） as adjunctive therapy for liver cancer. Of the 4 proprietary Chinese medicine injections-treated groups, Aidi Injection is better than the other 3 in cost-effectiveness. Aidi Injection as adjunctive therapy plus interventional therapy is an optimal regimen economically in the treatment of patients with advanced liver cancer.

关 键 词：肝癌 成本-效果 艾迪注射液 康莱特注射液 榄香烯注射液 消癌平注射液 

分 类 号：R979.1[医药卫生—药品]